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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYMutations in leucine-rich repeat kinase 2 (LRRK2) are the most-common genetic determinants of Parkinson’s disease (PD). The G2019S
mutation is detected most frequently and is associated with increased kinase activity. Whereas G2019S mutant dopamine neurons
exhibit neurite elongation deficits, the effect of G2019S on other neuronal subtypes is unknown. As PD patients also suffer from non-
motor symptoms thatmay be unrelated to dopamine neuron loss, we used induced pluripotent stem cells (iPSCs) to assessmorphological
and functional properties of peripheral sensory neurons. LRRK2 G2019S iPSC-derived sensory neurons exhibited normal neurite length
but had largemicrotubule-containing neurite aggregations. Additionally, LRRK2G2019S iPSC-derived sensory neurons displayed altered
calcium dynamics. Treatment with LRRK2 kinase inhibitors resulted in significant, but not complete, morphological and functional
rescue. These data indicate a role for LRRK2 kinase activity in sensory neuron structure and function, which when disrupted, may
lead to sensory neuron deficits in PD.INTRODUCTION
Parkinson’s disease (PD) is recognized by a variety of pro-
gressive motor symptoms, with themajority of PD patients
also suffering from non-motor symptoms that can occur
before motor symptoms appear and may be independent
of dopamine neuron loss (Gaig et al., 2014; Pont-Sunyer
et al., 2015; van der Heeden et al., 2014). Evidence of path-
ological changes in the dorsal root ganglia and the vagus,
glossopharyngeal, and internal superior laryngeal periph-
eral nerves is rapidly accumulating (Mu et al., 2013a,
2013b). Lewy body pathology has also been observed in
the dorsal vagus ganglion and parasympathetic nuclei,
enteric nervous system, and cardiac and pelvic plexus (Wa-
kabayashi and Takahashi, 1997; Orimo et al., 2008; Beach
et al., 2010; Tysnes et al., 2010; Cersosimo and Benarroch,
2012). It remains to be determined whether peripheral
neuron damage precipitates the development of non-mo-
tor symptoms in PD, but focused analysis on the peripheral
nervous system may ultimately provide information lead-
ing to broad therapeutic intervention.
Most cases of PD are sporadic, but familial mutations ac-
count for nearly 10% of patients with PD (Toulouse and
Sullivan, 2008). Mutations in leucine-rich repeat kinase 2
(LRRK2) cause an autosomal dominant form of PD that is
clinically indistinguishable from sporadic PD (Marras
et al., 2011; Alcalay et al., 2013; Gatto et al., 2013; Trinh
et al., 2014). LRRK2 is a multi-domain kinase that exists
as a dimer under physiological conditions, and several
studies have indicated that the G2019S mutation signifi-
cantly increases kinase activity (West et al., 2005; Greggio
et al., 2006; Jaleel et al., 2007; Luzo´n-Toro et al., 2007;Stem Cell RepAnand et al., 2009; Covy and Giasson, 2009). Although
the underlying pathogenesis of PD remains poorly under-
stood, increased LRRK2 kinase activity likely plays a key
role in LRRK2-linked PD (Greggio et al., 2006; MacLeod
et al., 2006; Smith et al., 2006; Lee et al., 2010; Deng
et al., 2011).
The function of LRRK2 remains to be fully elucidated, but
studies have demonstrated a role for LRRK2 in neurite elon-
gation and arborization. Cultured dopaminergic neurons
from human LRRK2-G2019S-expressing transgenic mice
and patient-specific induced pluripotent stem cells (iPSCs)
display shortened neurites and reduced neurite complexity
(Ramonet et al., 2011; Cooper et al., 2012; Sa´nchez-Dane´s
et al., 2012; Reinhardt et al., 2013). Themolecular basis un-
derlying the effects of LRRK2 on neurite growth and integ-
rity is not known, though putative LRRK2 effectors have
been implicated in the regulation of neurite outgrowth
including ezrin, radixin, and moesin (ERM), which play
roles in cytoskeletal dynamics. Increased LRRK2 activity
has been correlated with increased ERM phosphorylation
and decreased axon extension (Parisiadou et al., 2009).
Although sensory nerve disruption in PD has been re-
ported by functional assessments of cutaneous sensory
nerve endings and post-mortem analysis (Dabby et al.,
2006; Ikemura et al., 2008; Nolano et al., 2008; Shishido
et al., 2010; Toth et al., 2010), there are limited data on
the effect of LRRK2 on sensory neuron structure and func-
tion. We sought to investigate whether PD mutations
confer intrinsic defects in sensory neuron structure and
function using iPSCs. We compared sensory neurons
derived from two PD patients with homozygous LRRK2
G2019S mutations and one asymptomatic patientorts j Vol. 5 j 1039–1052 j December 8, 2015 j ª2015 The Authors 1039
Table 1. Description of the Different Control and PD Cell Lines Used
Line Mutation Sex
Age of
Sampling
Age of
Onset
Method of
Reprogramming Source
GM03814
(control 1)
N/A F unknown NA lentiviral purchased fibroblasts from Coriell; iPSC
generation described in Ebert et al., 2009
GM02183
(control 2)
N/A F 21 NA Sendai purchased fibroblasts from Coriell; iPSC
generation in house
K3 (control 3) N/A M newborn NA transient transfection
of plasmid DNA encoding
reprogramming factors
iPSCs obtained from Dr. Stephen Duncan,
described in Si-Tayeb et al., 2010
ND34391*E
(SNCA 33)
SNCA
triplication
F 55 50 retroviral purchased iPSC line from Coriell
ND40019*C
(LRRK2 G2019S het)
G2019S
heterozygous
M unknown NA retroviral purchased iPSC line from Coriell
ND35367*C
(LRRK2 G2019S 1)
G2019S
homozygous
M 79 50 retroviral purchased iPSC line from Coriell
ND40018*C
(LRRK2 G2019S 2)
G2019S homozygous F 60 48 retroviral purchased iPSC line from Coriellheterozygous for LRRK2 G2019S to one PD patient with
a-synuclein (SNCA) triplication and three unaffected indi-
viduals. Dopamine neurons derived from the mutant
LRRK2 lines showed shortened neurites and reduced neu-
rite branching, consistent with other well-characterized
models of LRRK2 PD. In contrast, LRRK2 G2019S iPSC-
derived sensory neurons exhibited normal neurite
outgrowth but increased cytoskeletal aggregations and
altered calcium dynamics compared to control or SNCA
iPSC-derived sensory neurons. Treatment with LRRK2
kinase inhibitors resulted in significant but incomplete
morphological and functional rescue. Together, these
data indicate that excessive LRRK2 kinase activity can nega-
tively impact sensory neuron structure and function and
may play a role in the development of sensory dysfunction
in PD.RESULTS
Sensory Differentiation and Characterization from PD
and Control iPSCs
To examine the functional properties of PD sensory neu-
rons, we utilized human iPSCs derived from multiple PD
patients (Table 1). We cultured iPSCs from an a-synuclein
triplication line (referred to as SNCA (33)), two homozy-
gous LRRK2 G2019S lines (referred to as LRRK2 G2019S 1
and 2), a heterozygous LRRK2 G2019S line (referred to as
LRRK2 G2019S het), and three unaffected control lines
(referred to as control 1, 2, and 3). The iPSCs were grown
as adherent monolayers and then differentiated into
peripherin-positive peripheral sensory neurons using a pre-1040 Stem Cell Reports j Vol. 5 j 1039–1052 j December 8, 2015 j ª2015 Thviously established protocol (Chambers et al., 2012). Gen-
eration of peripherin- and bIII-tubulin-positive neurons
was assessed by immunocytochemistry at 4 and 6 weeks
of differentiation (Figure 1A). Importantly, all PD and con-
trol iPSCs generated equivalent numbers of peripheral
sensory neurons based on the expression of bIII tubulin
(30%–40%) and peripherin (20%; Figures 1B and 1C)
with similar neurite lengths (Figure 1D). Additional immu-
nocytochemical and functional characterization of the
sensory neuron subtype of TrkA- and TRPV1-expressing
nociceptors showed differentiation efficiency was equiva-
lent across all iPSC lines (Figure S1).
Neurite Outgrowth Abnormalities and Aggregate
Formation in LRRK2 G2019S iPSCs
Despite the fact that all PD iPSC lines tested generated
similar numbers of peripheral sensory neurons, LRRK2
G2019S iPSCs exhibited specific neurite deficits. LRRK2
G2019S iPSC-derived sensory neurons displayed signifi-
cantly more and larger neurite aggregates compared to
control and SNCA (33) iPSC-derived sensory neurons (Fig-
ures 2A–2C). Neurite aggregates have been observed in
many different neurodegenerative diseases including PD
(MacLeod et al., 2006) and may be an indicator of early
stages of axonopathy. Neurite aggregates may be a prom-
inent feature of the LRRK2 G2019S mutation as the
phenotype was not observed in SNCA (33) iPSC-derived
sensory neurons (Figure 2B) and was also absent from
peripheral sensory neurons derived from other diseased
iPSCs (Schwab and Ebert, 2014). Immunocytochemistry
for ATF3, a transcription factor activated in sensory neu-
rons following nerve injury (Tsujino et al., 2000; Linda˚e Authors
Figure 1. Peripherin-Positive Sensory Neurons at 4 and 6 Weeks of Differentiation
(A) Control and PD iPSCs acquired a bIII tubulin+ (green)/peripherin+ (red) sensory neuron phenotype. Nuclei are labeled with Hoechst
(blue).
(B and C) Quantification of peripherin+ (B) and bIII tubulin+ (C) sensory neurons showed no significant difference in neuronal differ-
entiation efficiency between control and PD iPSCs.
(D) There was no difference in neurite length between control and PD iPSC-derived sensory neurons.
n.s., not significant by one-way ANOVA at each time point; n = 6 independent experiments. The scale bar represents 50 mm. See also
Figure S1.et al., 2011), was not increased in LRRK2 G2019S cultures
(data not shown), indicating minimal peripheral nerve
damage.
The sensory neuron data are in contrast to the phenotype
observed in LRRK2 G2019S iPSC-derived dopamine neu-
rons. Similar to previous studies (Cooper et al., 2012; Sa´n-
chez-Dane´s et al., 2012; Reinhardt et al., 2013), we found
that LRRK2 G2019S iPSC-derived dopamine neurons ex-
hibited significantly shortened neurites and reduced neu-
rite arborization but no increase in neurite aggregation
compared to controls (Figures S2A–S2D). We hypothesized
that neurite length was too short to induce significant
aggregate formation in LRRK2 G2019S iPSC-derived dopa-Stem Cell Repmine neurons. To test this, we cultured LRRK2 G2019S
iPSC-derived dopamine neurons with nerve growth factor
(NGF), a potent growth factor for neurite outgrowth used
in the sensory neuron differentiation medium. NGF treat-
ment significantly restored neurite length to control levels
compared to untreated LRRK2 G2019S dopamine neurons
(Figure S2E), but aggregate numbers were unchanged
(data not shown). Similarly, treatment with the LRRK2 ki-
nase inhibitor LRRK2-IN-1 also restored neurite length
without the development of neurite aggregates (data not
shown). We next considered that levels of phosphory-
lated and total LRRK2 may differentially affect dopamine
and sensory neurons; however, we found no significantorts j Vol. 5 j 1039–1052 j December 8, 2015 j ª2015 The Authors 1041
Figure 2. LRRK2 G2019S iPSC-Derived Sensory Neurons Display Neurite Aggregate Formation
(A) LRRK2 G2019S sensory neurons showed abnormal neurite patterns and increased aggregates along the neurites (white arrows).
(B) The number of aggregates per neurite was significantly increased in LRRK2 G2019S neurons compared to all other groups by one-way
ANOVA within each time point.
(C) The aggregate area was significantly increased in both LRRK2 G2019S 1 and 2 compared to all other groups by Kruskal-Wallis test.
*p < 0.01; n = 4 independent experiments. The scale bar represents 50 mm. See also Figure S2.differences in protein expression between the two neuron
subtypes (Figure S2F). These data indicate that LRRK2
G2019S alters cytoskeletal structure but that defects mani-
fest differently in sensory neurons and dopamine neurons.
We next sought to determine the composition of the
neurite aggregates. Aggregates showed positive staining
for peripherin and bIII tubulin, which are intermediate
filament and microtubule proteins, respectively (Fig-
ure 3A). A proportion of aggregates were positive for the
microtubule-associated protein tau (Figure 3A), although
we did not observe tau phosphorylation by immunocyto-
chemistry (data not shown). However, by western blot,
we do observe an overall increase in tau and phosphory-
lated tau levels in LRRK2 G2019S sensory neuron cultures
compared to control and SNCA (33) (Figures 3B–3D).
Neurite aggregates were also positive for microtubule-
associated protein 2 (MAP2) (Figure 3A). We found that1042 Stem Cell Reports j Vol. 5 j 1039–1052 j December 8, 2015 j ª2015 Thsome aggregates expressed LRRK2 (Figure 3A), but we
did not observe LRRK2 phosphorylation by immunocyto-
chemistry (data not shown). Overall expression of SNCA
was low but highly variable from neuron to neuron as
shown by immunocytochemistry (Figure S3A) and within
the whole culture as shown by western blot (Figure S3B).
As expected, the SNCA (33) iPSC line had a global in-
crease in SNCA expression compared to controls (Figures
S3A–S3C) consistent with a gene triplication mutation.
SNCA was increased in one LRRK2 G2019S iPSC line,
but not the others (Figures S3B and S3C), suggesting
that SNCA levels do not accurately predict the develop-
ment of aggregates in this system. At the aggregate level,
some aggregates did express SNCA (Figure S3A), but the
majority did not (Figure 3A). Finally, ubiquitin expression
was not observed in the neurite aggregates (Figure 3A).
Taken together, these results suggest that aggregatese Authors
Figure 3. Aggregates Are Comprised of Cytoskeletal Proteins
(A) LRRK2 G2019S aggregates were positive (indicated by arrows) for bIII tubulin (green) and peripherin (red), tau (green), MAP2 (red),
and LRRK2 (green). Aggregates were generally negative (indicated by arrowheads) for SNCA and ubiquitin (green).
(B–D) LRRK2 G2019S sensory neuron cultures display significantly increased levels of (B and C) tau and (B and D) phospho-tau by western
blot and densitometry. *p < 0.01 by ANOVA; n = 6 independent experiments.
The scale bar represents 50 mm. See also Figure S3.contain axonal and dendritic microtubule proteins and
are likely distinct from classical Lewy bodies and Lewy
neurites.
Altered Calcium Dynamics in LRRK2 G2019S iPSC-
Derived Sensory Neurons
Compared to control and SNCA (33), sensory neuronswith
LRRK2 G2019S mutations showed decreased calcium-
mediated response to depolarization with 50 mM KCl (Fig-
ure 4). Sensory neurons derived from each of the LRRK2
G2019S iPSC lines showed significant differences in this
response compared to all controls and SNCA (33) (Figures
4A–4C). Next, we investigated whether impaired calcium
signaling affected autophagy as has been reported previ-
ously (Go´mez-Suaga et al., 2012).We found a significant in-Stem Cell Repcrease in p62 and LC3-II protein levels in LRRK2 G2019S
iPSC-derived sensory neurons compared to control and
SNCA (33) (Figures S4A–S4C). Collectively, these data sug-
gest that the G2019S mutation compromises the ability of
the iPSC-derived sensory neurons to efficiently respond to
calcium signaling.
Pharmacological Inhibition of LRRK2 Kinase Activity
Partially Rescues Morphological Abnormalities
To assess whether hyper-kinase activity was contributing
to morphological abnormalities in LRRK2 G2019S iPSC-
derived sensory neurons, we treated sensory neurons with
three different LRRK2 kinase inhibitors: LRRK2-IN-1;
GSK2578215A; and CZC25146. Studies have shown
LRRK2 is phosphorylated at Ser935 (Dzamko et al.,orts j Vol. 5 j 1039–1052 j December 8, 2015 j ª2015 The Authors 1043
Figure 4. LRRK2 G2019S and LRRK2 G2019S het iPSC-Derived Sensory Neurons Display Abnormal Calcium Dynamics
(A) Representative calcium imaging traces of at least ten individual sensory neurons are shown for each line at 4 weeks of differentiation.
KCl indicates the time at which the depolarizing stimulus was added to the cultures.
(B and C) Sensory neurons from each of the LRRK2 G2019S iPSC lines displayed a significantly reduced response to KCl-induced depo-
larization at 4 and 6 weeks of differentiation compared to controls and SNCA (33). *p < 0.01 by ANOVA to the controls and Student’s t test
to SNCA (33); n = 6 independent experiments, totalingR100 neurons from each iPSC line.
See also Figure S4.2010; Deng et al., 2011; Reith et al., 2012). Using western
blot analysis, we observed that untreated LRRK2 G2019S
sensory neurons showed increased phosphorylation at
Ser935 compared to control; as an indication of the ef-
fectiveness of kinase inhibition, western blot analysis
indicated that all three kinase inhibitors reduced Ser935
phosphorylation without substantial alterations in total
LRRK2 levels (Figure 5A). Kinase inhibition did not affect
cell survival or differentiation (Figures 5B and 5C), but it
did result in a significant decrease in neurite aggregation
and reduced aggregate size compared to the untreated
LRRK2 G2019S condition (Figures 5D and 5E). LRRK2-
IN-1 treatment did lead to increased aggregate formation,
and all three inhibitors increased aggregate size in control
sensory neurons. This negative effect on the control neu-
rons may be due to possible off-target effects of LRRK2
kinase inhibition (Luerman et al., 2014). Additionally,
not all inhibitors were equally effective (Figures 5D and
5E). Nevertheless, these results suggest that excessive
LRRK2 kinase activity contributes to neurite aggregate
formation.1044 Stem Cell Reports j Vol. 5 j 1039–1052 j December 8, 2015 j ª2015 ThPharmacological Inhibition of LRRK2 Kinase Activity
Improves Calcium Dynamics
To assess whether hyper-kinase activity was also contrib-
uting to diminished KCl-mediated calcium responses in
LRRK2 G2019S iPSC-derived sensory neurons, we treated
sensory neuron cultures with LRRK2-IN-1, GSK2578215A,
and CZC25146 kinase inhibitors for 2 weeks starting at
2 weeks of differentiation (Figure 6A). Live-cell calcium im-
aging analysis of sensory neurons treated with LRRK2
kinase inhibitors showed a significant increase in KCl-
induced calcium response in LRRK2 G2019S sensory
neuron cultures; however, all treated groups were still
significantly reduced compared to untreated control levels
(Figures 6A and 6B). However, only treatment with
GSK2578215A significantly improved calcium response
to KCl depolarization in LRRK2 G2019S het sensory neu-
rons, which may be indicative of greater LRRK2 specificity
(Reith et al., 2012). In contrast, control sensory neurons ex-
hibited a decreased calcium response to KCl after
CZC25146 treatment, whichmay be attributed to off-target
effects. We tested whether lower dosages of GSK2578215Ae Authors
Figure 5. Pharmacologically Inhibiting LRRK2 Kinase Activity Partially Rescues Morphological Abnormalities
(A) LRRK2-IN-1, CZC25146, and GSK2578215A treatment reduced phosphorylation of S935 in LRRK2 G2019S sensory neurons as shown by
western blot and densitometry. GAPDH was used as a protein loading control. For reference, longer exposure times allowed for the
detection of S935 in control and SNCA (33) samples.
(B and C) Representative peripherin (red) and bIII tubulin (green) images are shown for untreated and inhibitor treated conditions, with
no significant impact on sensory neuron development or survival by one-way ANOVA. Nuclei are labeled in blue.
(D) LRRK2-IN-1, CZC25146, and GSK2578215A treatment significantly reduced the number of aggregates in sensory neurons derived from
LRRK2 G2019S 1 and 2 compared to their respective untreated condition by one-way ANOVA. LRRK2-IN-1 and GSK2578215A treatment
reduced neurite aggregation in LRRK2 G2019S het compared to its untreated condition by one-way ANOVA. CZC25146 treatment induced
significant aggregate formation in control cells compared to its untreated condition by one-way ANOVA.
(E) LRRK2-IN-1, CZC25146, and GSK2578215A treatment of LRRK2 G2019S 2 resulted in a significant decrease in neurite aggregate area,
whereas only CZC25146 and GSK2578215A significantly rescued neurite aggregate area in LRRK2 G2019S 1. Only LRRK2-IN-1 significantly
decreased aggregate area in LRRK2 G2019S het. All three inhibitors increased aggregate area in control cells by Kruskal-Wallis test.
n.s., not significant within each cell line. *p < 0.01 compared to untreated control and #p < 0.01 comparing treatment to the respective
untreated condition. The scale bar represents 50 mm. n = 3 independent experiments totalingR50 neurons for each iPSC line.(0.1 and 0.5 mM) for shorter durations would still be effec-
tive. An acute 1-day treatmentwasnot sufficient to alter cal-
cium responses to depolarization (data not shown). Lower
doses were mostly ineffective, but a 1-week treatmentStem Cell Repwith 1 mM was sufficient to significantly improve calcium
responses to depolarization (Figure S5). Higher doses were
not tested in an effort to avoid exacerbating anynegative ef-
fects in control cells (e.g., Figures 5E and 6B). Interestingly,orts j Vol. 5 j 1039–1052 j December 8, 2015 j ª2015 The Authors 1045
Figure 6. Pharmacologically Inhibiting LRRK2 Kinase Activity Partially Rescues Calcium Signaling Deficits
(A) Representative traces of at least ten sensory neurons are shown for control 3 and LRRK2 G2019S 1 untreated and kinase-inhibitor-
treated conditions at 4 weeks of differentiation.
(B) LRRK2-IN-1, CZC25146, and GSK2578215A treatment significantly increased calcium response to KCl in LRRK2 G2019S 1 sensory
neurons. Only GSK2578215A treatment significantly increased calcium response to KCl in LRRK2 G2019S 2 and het sensory neurons. Control
sensory neurons treated with CZC25146 resulted in a significantly decreased calcium response to KCl. *p < 0.01 compared to untreated
control and #p < 0.01 comparing treatment to the respective untreated condition by Kruskal-Wallis test. n = 3 independent experiments
totalingR100 neurons for each iPSC line.
See also Figure S5.the autophagy markers p62 and LC3-II were unaffected by
kinase inhibition (Figures S4A–S4C). These results suggest
that increased kinase activity due to the G2019S mutation
partially contributes to calcium-related defects in LRRK2
G2019S iPSC-derived sensory neurons.DISCUSSION
PD patients suffer from both motor and non-motor symp-
toms, and due to the differentiation capacity of iPSCs, we
can take advantage of this system to study multiple cell
types that may be impacted by disease processes. Consis-
tent with other reports (Cooper et al., 2012; Sa´nchez-Dane´s
et al., 2012; Reinhardt et al., 2013), we show that LRRK2
G2019S iPSC-derived dopamine neurons display shortened
neurites and reduced branching compared to controls.
However, the same LRRK2 G2019S mutation creates a
different phenotype in peripheral sensory neurons. Specif-
ically, we find neurite length is comparable to control cells,1046 Stem Cell Reports j Vol. 5 j 1039–1052 j December 8, 2015 j ª2015 Thbut the neurites harbor large cytoskeletal aggregates. Rein-
hardt and colleagues (2013) had previously found that
Brn3a-positive sensory neurons derived from heterozygous
LRRK2 G2019S iPSCs did not exhibit increased cell death
following treatment with rotenone, but no other aspects
of sensory neuron structure or function have previously
been studied. Although very little is known about the cause
of somatosensory symptoms in PD, the observation of neu-
rite aggregates within sensory neurons aligns with PD pa-
tients exhibiting peripheral nervous system impairment
and may be a pathological feature of PD (Nolano et al.,
2008; Donadio et al., 2014; Doppler et al., 2014). Addition-
ally, intermediate filament- and peripherin-containing ag-
gregates are commonly found in the peripheral axon of
motor neurons in amyotrophic lateral sclerosis (Xiao
et al., 2006), suggesting peripheral neurons and central
neurons with peripheral targets may undergo common
alterations in neurodegenerative diseases.
Using immunocytochemical analysis, we found that
LRRK2 G2019S iPSC-derived sensory neurons displayede Authors
neurite aggregations comprised of PD-associated proteins
b-tubulin, MAP2, Tau, LRRK2, and SNCA. b-tubulin, a
component of Lewy bodies, has been shown to directly
interact with LRRK2, which regulates tubulin phosphoryla-
tion and acetylation (Law et al., 2014). Moreover, tubulin
interacts with a number of other PD-related proteins
including SNCA, parkin, and tau (Alim et al., 2002; Yang
et al., 2005; Gillardon, 2009; Kawakami et al., 2012; Law
et al., 2014), which likely implicates microtubule dysfunc-
tion as a common mechanism leading to the clinical and
pathological hallmarks of PD (Cartelli et al., 2012). Consis-
tent with this, MAP2-positive neurite aggregates have been
identified in dopaminergic and non-dopaminergic neu-
rons in post-mortem PD brain (D’Andrea et al., 2001).
Tau has been implicated in the pathogenesis of PD in recent
genome-wide screens (Simo´n-Sa´nchez et al., 2009; Edwards
et al., 2010) and is seen in animalmodels expressing LRRK2
mutations (Li et al., 2009b; Lin et al., 2010; Melrose et al.,
2010). LRRK2 has been shown to facilitate tau phosphory-
lation in a kinase-independent manner (Shanley et al.,
2015), and our tau data align with previously reported
data in LRRK2 G2019S and I2020T iPSC-derived neurons
(Reinhardt et al., 2013; Ohta et al., 2015). Tau hyperphos-
phorylation has been shown to favor tau detachment
from microtubules (Lindwall and Cole, 1984) that can
lead to neurofibrillary tangle formation. Moreover, in a
hLRRK2 (R1441G) BAC transgenic mouse model, frag-
mented axons, axonal spheroids, and dystrophic neurites
were observed and found to be associated with abnormally
phosphorylated tau (Li et al., 2009a). Together with our
data, these observations suggest a role of LRRK2 in tau-
related neuronal pathology, which may be contributing
to the increased neurite aggregate formation in iPSC-
derived sensory neurons.
The contribution of LRRK2 to PD pathology has yet to be
fully elucidated. LRRK2 has been proposed to act upstream
of SNCA and tau to promote aggregation, but it may also
act independently to promote neuron loss in the absence
of aggregate pathology (Taymans and Cookson, 2010).
Additionally, in some experimental cell culture systems,
LRRK2 G2019S mutation has been shown to generate
numerous protein aggregates (Greggio et al., 2006),
whereas in others it does not (Kett et al., 2012). Together,
these data indicate a need for better understanding of
cell-type-specific LRRK2 functions. Our data also suggest
that the aggregates are distinct from traditional Lewy
bodies and form independent of SNCA expression levels.
The lack of aggregate formation in SNCA (33) iPSC sensory
neurons may be further indication of divergent LRRK2 and
SNCA pathways leading to cellular dysfunction in PD. The
low level of SNCA-positive aggregations in the LRRK2 iPSCs
is somewhat surprising as many LRRK2 cases show SNCA
Lewy body pathology (Giasson and Van Deerlin, 2008; Ha-Stem Cell Repsegawa et al., 2009). However, some LRRK2 PD patients do
not develop Lewy body pathology (Cookson et al., 2008),
and a number of experimental models of LRRK2-associated
PD exhibit protein aggregations and/or inclusions that do
not associate with SNCA (Waxman et al., 2009; Tsika
et al., 2015). Differences in experimental models, such as
species, neuron subtype, LRRK2 expression levels, and anti-
body epitopes and/or specificity may contribute to varia-
tions in results (Zhu et al., 2006; Melrose et al., 2007).
Nevertheless, these data all indicate mutant LRRK2 can
disrupt neurite integrity in multiple neuronal systems
and may promote neuron dysfunction and death. Specif-
ically, how LRRK2 is affecting microtubule stability in sen-
sory neurons needs further investigation, but the robust
aggregate phenotype found in LRRK2 G2019S iPSC neu-
rons will be a valuable system to address this.
Using live-cell calcium imaging analysis, we found that
LRRK2 G2019S iPSC-derived sensory neurons display
diminished calcium responses to KCl depolarization. As
calcium is critical for proper neuronal signaling and func-
tion, any perturbation could be detrimental. Dysregulated
calcium is evident in mutant LRRK2 neurons. For example,
others showed that mutant LRRK2-expressing mouse
cortical neurons had reduced calcium recovery and efflux
(Cherra et al., 2013). Altered calcium levels can lead to ab-
errations in lysosomal clearance, followed by an increase in
proteostatic stress. In this regard, Go´mez-Suaga et al. (2012)
showed that overexpression of wild-type or G2019S LRRK2
caused an increase in autophagosomes through calcium-
dependent activation of the CaMKK/AMPK pathway,
which could be inhibited by calcium chelation. Autopha-
gosome accumulation in the LRRK2 G2019S iPSC-derived
sensory neurons further indicates impairment of the auto-
phagy-lysosome system in LRRK2-mediated PD. However,
the neuron-subtype-specific consequences of calcium dys-
regulation and subsequent altered autophagy signaling
remain to be determined in relation to pathological mech-
anisms in PD.
Finally, our findings further support the idea that kinase
activity is playing a role in LRRK2-G2019S-induced
neuronal dysfunction. Inhibition of LRRK2 kinase activity
using LRRK2-IN-1, GSK2578215A, or CZC25146 resulted
in partial but significant functional and morphological
rescue in homozygous and heterozygous LRRK2 G2019S
iPSC-derived sensory neurons. Individual kinase inhibitors
show differing efficacy in the parameters tested, but treat-
ment with GSK2578215Amost consistently resulted in sig-
nificant aggregate reduction and calcium signaling
improvement in both the homozygous and heterozygous
contexts. However, neither outcome measure was rescued
to control levels, nor were levels of autophagosome
markers improved. This could be due to suboptimal inhib-
itor dosages or treatment paradigms, but it is also possibleorts j Vol. 5 j 1039–1052 j December 8, 2015 j ª2015 The Authors 1047
that other functional domains of LRRK2 contribute to sen-
sory neuron dysfunction. For example, mutations in the
GTPase domain result in neurite aggregations in transgenic
mice (Li et al., 2009b). GTPase activity has been shown to
modulate kinase activity, and it has been proposed that
the GTPase and kinase domains may reciprocally regulate
each other to direct the function of LRRK2 (Biosa et al.,
2013), thereby necessitating further consideration of the
potential pathogenic interplay between LRRK2 functional
domains.
Disease modeling with iPSCs can be challenging due to
inherent patient variability and line-to-line differences
(Hu et al., 2010; Boulting et al., 2011). Importantly, very
few differences were observed among the three indepen-
dent control lines. The SNCA (33) iPSC line was not
different from controls in the parameters tested, but one
SNCA (33) line is not sufficient to conclude this line does
not exhibit other PD-related phenotypes. The two homo-
zygous LRRK2 G2019S iPSC lines used here showed slight
variation in the extent of the dysfunction, with LRRK2
G2019S 1 generally being more affected. However, both
lines were consistently impaired relative to control cells
and the SNCA (33) line. The heterozygous LRRK2 G2019S
iPSC-derived sensory neurons exhibited a less-severe
phenotype than sensory neurons derived from either ho-
mozygous LRRK2 G2019S iPSC line. This could be due to
the fact that the heterozygous LRRK2 G2019S iPSC line
was generated from an asymptomatic patient. Alterna-
tively, it could be due to a dosage effect of mutant LRRK2.
Nevertheless, the heterozygous mutant LRRK2 iPSC-
derived neurons did exhibit significant structural and func-
tional abnormalities consistent with the dominant nature
of LRRK2 mutations. Despite minor variations among the
three LRRK2 G2019S iPSC lines, our data report a robust
aggregate and calcium phenotype in LRRK2 G2019S iPSC-
derived sensory neurons that provides the foundation for
additional optimization and evaluation across a larger
cohort of LRRK2 patient samples. The iPSC-based model
of PD offers a valuable tool to study the pathophysiology
of LRRK2-related defects in multiple cell types affected in
PD and may provide a mechanistic link between cytoskel-
etal changes, neuron dysfunction, and the appearance of
motor and non-motor symptoms in PD.EXPERIMENTAL PROCEDURES
Cell Culture
Human iPSCs were obtained from commercially available samples
of an SNCA triplication line (ND34391*E; Coriell Institute), two
LRRK2 G2019S lines (ND35367*C and ND40018*C; Coriell Insti-
tute), and a heterozygous LRRK2G2019S line (ND40019*C; Coriell
Institute). Three previously characterized unaffected control lines
were used (GM003814 Coriell Institute, GM02183 Coriell Insti-1048 Stem Cell Reports j Vol. 5 j 1039–1052 j December 8, 2015 j ª2015 Thtute, and iPSK3; Ebert et al., 2009; Si-Tayeb et al., 2010; HD iPSC
Consortium, 2012). iPSCs were grown in feeder-free conditions
on Matrigel substrate in Nutristem medium (Stemgent) and used
between passages 5 and 15. Neural progenitor cells (EZ Spheres)
were generated and maintained as previously described (Ebert
et al., 2013). The use of iPSCs was approved by theMedical College
of Wisconsin’s Human Stem Cell Research Oversight Committee.
Neural Differentiation
EZ spheres were differentiated into dopamine neurons using
FGF-8, purmorphamine, and growth factors as previously
described (Ebert et al., 2013). Induction of sensory neurons was
accomplished using an established protocol (Chambers et al.,
2012). For kinase inhibition experiments, 1 mM LRRK2-IN-1,
1 mM GSK2578215A, and 200 nM CZC25146 (kindly provided by
Sabine Hilfiker but commercially available through Tocris and
Sigma) was added at the 2-week time point and freshly supple-
mented every feeding for a total of 2 weeks. DMSO (1 mM and
200 nM) was used as the vehicle control.
Calcium Imaging
iPSC-derived sensory neuron cultures were functionally tested us-
ing ratiometric live-cell calcium imaging using dual-wavelength
fluorescent calcium indicator FURA-2AM (Life Technologies) to
detect intracellular calcium levels as described previously (Schwab
and Ebert, 2014). Metafluor imaging software was used to detect
and analyze intracellular calcium changes throughout the experi-
ment (Molecular Devices), where aR20% increase in intracellular
calcium from baseline constituted a response.
Western Blot
Whole-cell lysates were isolated from sensory neuron cultures us-
ing 13 Chaps Cell Extract buffer with protease inhibitors (Cell
Signaling Technology). Twenty micrograms of protein was run
on 10% Tris-HCl polyacrylamide gels (Bio-Rad), transferred to
PVDF membrane (Millipore), and probed following standard
methods. Primary antibodies used were rabbit anti-GAPDH
(Sigma-Aldrich; G9545), rabbit anti-LRRK2 phospho S935 (Abcam;
ab133450), rabbit anti-LRRK2 (Cell Signal; 5559), rabbit anti p62
(Novus; NBP1-48320), rabbit anti-LC3B (Cell Signal; 3868), mouse
anti PHF-Tau (Thermo; MN1020), mouse anti-Tau (Cell Signal;
4019), and mouse anti-SNCA (DSHB; H3C-s). Secondary anti-
bodies anti-rabbit IgG HRP (Promega; W4011) and anti-mouse
IgG HRP (Promega; W4021) were used.
Immunocytochemistry
Plated cells were fixed in 4% paraformaldehyde in PBS (pH 7.4) for
20min at room temperature. Nonspecific labelingwas blocked and
the cells permeabilized prior to primary antibody incubation. Cells
were subsequently labeled with the appropriate fluorescently
tagged secondary antibodies. Hoechst nuclear dyewas used to label
nuclei. Primary antibodies used were rabbit anti-peripherin (Milli-
pore; AB1530), mouse anti-bIII tubulin (Promega; G7121), rabbit
anti-TRPV1 (Novus Biologicals; NBP1-97417), mouse anti-tau
(Cell Signal; 4019), rabbit anti-MAP2 (Cell Signal; 4542), rabbit
anti-tyrosine hydroxylase (Pel-Freez; P40101-150), mouse
anti-SNCA (DSHB; H3C-s), mouse anti-SNCA 211 (Thermo;e Authors
MA5-12272), mouse anti-ubiquitin (Novus Biologicals; NB300-
130SS), mouse anti-LRRK2 (NeuroMab; clone N241A/34; 73-
253), rabbit anti-LRRK2 phospho S935 (Abcam; ab133450), mouse
anti-phospho-PHF-tau pSer202+Thr205 (Thermo Scientific; AT8;
MN1020), and rabbit anti-ATF3 (Santa Cruz Biotechnology;
C-19; sc-188). Secondary antibodies included donkey anti-mouse
AF488 (Invitrogen; A21202) and goat anti-rabbit RhoRed (Invitro-
gen; R6394).Imaging and Data Analysis
Data for each iPSC line are from two to six independent experi-
ments with three technical replicates within each experiment.
Within each immunocytochemistry-based experiment, at least
five images were taken on each of at least three different fluores-
cently labeled coverslips per time point per line using a Nikon in-
verted microscope and Spot imaging software. The images were
analyzed for antigen specificity using MetaMorph Software
(Molecular Devices). Calcium imaging data were collected from
a minimum of three coverslips per time point from each line.
A minimum of 25 neurons were recorded from each coverslip.
In all experiments, the evaluator was blinded to the cell line
and treatment condition. Data were statistically analyzed with
Prism software (GraphPad) first for normality using the D’Agos-
tino-Pearson omnibus normality test, followed by the parametric
one-way ANOVA and Tukey’s multiple comparison test of signif-
icance or the non-parametric Kruskal-Wallis test and Dunn’s
multiple comparison test of significance; a = 0.05. Student’s
t test was used when appropriate. Data are presented as the
average ± SEM with the statistical test used indicated in each
figure legend.
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